# Lorlatinib Combinations in Lung Cancer

> **NCT04292119** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Massachusetts General Hospital** · enrollment: 96 (estimated)

## Conditions studied

- Lung Cancer
- Anaplastic Lymphoma Kinase Gene Translocation
- ROS1 Rearrangement
- Relapsed Cancer
- MET Amplification
- Resistant Cancer
- NSCLC

## Interventions

- **DRUG:** Lorlatinib
- **DRUG:** Crizotinib
- **DRUG:** Binimetinib
- **DRUG:** TNO155

## Key facts

- **NCT ID:** NCT04292119
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2021-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04292119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04292119, "Lorlatinib Combinations in Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04292119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*